1)日本神経学会:認知症疾患診療ガイドライン2017,医学書院,2017
2)内閣府:令和4年版高齢社会白書. https://www8.cao.go.jp/kourei/whitepaper/w-2022/zenbun/04pdf_index.html(2023年2月閲覧)
3)内閣府:平成29年版高齢社会白書. https://www8.cao.go.jp/kourei/whitepaper/w-2017/html/gaiyou/s1_2_3.html(2023年2月閲覧)
4)Schneider LS, et al:Lack of evidence for the efficacy of memantine in mild Alzheimer disease. Arch Neurol 68:991-998, 2011
5)Lockhart IA, et al:Safety and tolerability of donepezil, rivastigmine and galantamine for patients with Alzheimer's disease;Systematic review of the ‘real-world’ evidence. Dement Geriatr Cogn Disord 28:389-403, 2009
6)Bullock R, et al:Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period. Curr Med Res Opin 21:1317, 2005
7)Wilcock G, et al:A long-term comparison of galantamine and donepezil in the treatment of Alzheimer's disease. Drugs Aging 20:777, 2003
8)Stahl SM, et al:Co-use of donepezil and hypnotics among Alzheimer's disease patients living in the community. J Clin Psychiatry 64:466-472, 2003
9)Regenold WT, et al:Prescribing cholinesterase inhibitors for Alzheimer disease;Timing matters. Am Fam Physician 97:700, 2018
10)Rochon PA, Gurwitz JH:Optimising drug treatment for elderly people;The prescribing cascade. BMJ 315:1096-1099, 1997
11)Parsons C, et al:Withdrawal or continuation of cholinesterase inhibitors or memantine or both, in people with dementia. Cochrane Database Syst Rev 3:CD009081, 2021
for potentially inappropriate medication use in older adults. J Am Geriatr Soc 67:674-694, 2019
13)Hanlon JT, et al:A method for assessing drug therapy appropriateness. J Clin Epidemiol 45:1045-1051, 1992
14)Reconsidering medication appropriateness for patients late in life. Arch Intern Med 166:605-609, 2006
15)Isik AT, et al:Which cholinesterase inhibitor is the safest for the heart in elderly patients with Alzheimer's disease? Am J Alzheimers Dis Other Demen 27:171-174, 2012
16)Singh S, Dudley C:Discontinuation syndrome following donepezil cessation. Int J Geriatr Psychiatry 18:282-284, 2003